Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin

Clinical and Experimental Medicine

Volumn 5, Issue 2, 2005, Pages 80-85

  Rotschild, M ^a   Elias, N ^a   Berkowitz, D ^a   Pollak, S ^b   Shinawi, M ^a   Beck, R ^a   Bentur, L ^a,c  

^a MEYER CHILDREN S HOSPITAL   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Azithromycin; Bactericidal permeability increasing autoantibodies; Bactericidal permeability increasing protein; Cystic fibrosis; Macrolide

Indexed keywords

AUTOANTIBODY; AZITHROMYCIN; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLACEBO;

ADOLESCENT; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHI SQUARE TEST; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; KRUSKAL WALLIS TEST; LUNG FIBROSIS; MALE; PATIENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; RECORDING; WILCOXON SIGNED RANKS TEST;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; AUTOANTIBODIES; AZITHROMYCIN; BLOOD PROTEINS; CHILD; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; MEMBRANE PROTEINS; PLACEBOS;

PSEUDOMONAS AERUGINOSA;

EID: 23844501305     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10238-005-0070-7     Document Type: Article

References (32)

1. Brugiere O, Milleron B, Antoine M, Carette MF, Philippe C, Mayaud C (1996) Diffuse panbronchiolitis in an Asian immigrant. Thorax 51:1065-1067
2. Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A (1991) Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 58:145-149
3. Jaffe A, Bush A (2001) Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 31:464-473
4. Ordonez CL, Stulbarg M, Grundland H, Liu JT, Boushey HA (2001) Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. Pediatr Pulmonol 32:29-37
5. Wolter J, Seeney S, Bell S, Masel R McCormack J (2002) Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis: a randomized trial. Thorax 57:212-216
6. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M (2002) Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 360:978-984
7. Baumann U, Fischer JJ, Gudowius P et al (2001) Buccal adherence of pseudomonas aeruginosa in patients with cystic fibrosis under long-term therapy with azithromycin. Infection 29:7-11
8. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Cibene D, Coquillette S et al; Macrolide Study Group (2003) Azithromycin in patients with cystic fibrosis chronically infected with pseudomonas aeruginosa: a randomized controlled trial. JAMA 290:1749-1756
9. Southern KW, Barker PM, Solis A (2004) Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2:CD002203
10. Hansen CR, Pressler T, Koch C, Hoiby N (2005) Long term azithromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. J Cystic Fibrosis 4:35-40
11. Zhao MH, Jones SJ, Lockwood CM (1995) Bactericidal/permeability- increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis. Clin Exp Immunol 99:49-56
12. Zhao MH, Jayne DR, Ardiles LG, Culley F, Hodson ME, Lockwood CM (1996) Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis. Q J Med 89:259-265
13. Sediva A, Bartunkova J, Kolarova I, Hrusak O, Vavrova V, Macek M Jr et al (1998) Antineutrophil cytoplasmic autoantibodies (ANCA) in children with cystic fibrosis. J Autoimmun 11:185-190
14. Sediva A, Bartunkova J, Bartosova J, Jennette C, Falk RJ, Jethwa HS (2003) Antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein detected in children with cystic fibrosis inhibit neutrophil-mediated killing of Pseudomonas aeruginosa. Microbes Infect 5:27-30
15. Mahadeva R, Dunn AC, Westerbeek RC, Sharples L, Whitehouse DB, Carroll NR et al (1999) Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease. Clin Exp Immunol 117:561-567
16. Cooper T, Savige J, Nassis L, Paspaliaris B, Neeson P, Neil J et al (2000) Clinical associations and characterisation of antineutrophil protein and azurocidin. Rheumatol Int 19:129-136
17. Christoph A, Franziska T, Carmen CA, Martin HS (2000) Autoantibodies directed against bactericidal/permeability-increasing protein in patients with cystic fibrosis: association with microbial respiratory tract colonization. Infect Dis J 19:207-212
18. Carlsson M, Eriksson L, Erwander I, Wieslander J, Segelmark M (2003) Pseudomonas-induced lung damage in cystic fibrosis correlates to bactericidal-permeability increasing protein (BPI)-autoantibodies. Clin Exp Rheumatol 21:s95-s100
19. Schultz H, Schinke S, Mosler K, Herlyn K, Schuster A, Gross WL (2004) BPI-ANCA of pediatric cystic fibrosis patients can impair BPI-mediated killing of E. coli DH5alpha in vitro. Pediatr Pulmonol 37:158-164
20. Carbon C (1995) Clinical relevance of intracellular and extracellular concentrations of macrolides. Infection 23[Suppl 1]:10-14
21. Fisher JJ, Baumon U, Gudowius P et al (1999) Azithromycin reduces epithelial adherence of P aeruginosa in patients with cystic fibrosis. Pediatr Pulmonol Suppl 19:265 (Abstract)
22. Takizawa H, Desaki M, Ohtoshi T et al (1997) Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 156:266-271
23. Khan AA, Slifer TR, Araujo FG et al (1999) Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents 11:121-132
24. Desaki M, Takizawa H, Ohtosh T et al (2000) Erythromycin suppresses nuclear factor-kappa B and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun 267:124-128
25. Abe S, Nakomura H, Inove S et al (2000) Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am J Respir Cell Mol Biol 22:51-60
26. Morikawa K, Watabe H, Araake M et al (1996) Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. J Antimicrob Agents Chemother 40:1366-1370
27. Sugihara E (1997) Effect of macrolide antibiotics on neutrophil function in human peripheral blood. Kansenshogoku Zasshi 71:329-336 (abstract)
28. Villagrasa V, Berto L, Cortijo J et al (1997) Effects of erythromycin on chemoattractant-activated human polymorphonuclear leukocytes. Gen Pharmacol 29:605-609
29. Molinari G, Guzman CA, Pesce A et al (1993) Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother 31:681-688
30. Howe RA, Spencer RC (1997) Macrolides for the treatment of Pseudomonas aeruginosa infection? J Antimicrob Chemother 40:153-155
31. Kawamura SK, Iinuma Y, Hasegawa T et al (2000) Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. Antimicrob Agents Chemother 44:2869-2872
32. Yi MS, Britto MT, Wilmott RW, Kotagal UR, Eckman MH, Nielson DW et al (2003) Health values of adolescents with cystic fibrosis. J Pediatr 142:133-140